Dual Injection Approvals? A Comparison Of Indivior, Braeburn Buprenorphine Products

US FDA might approve Indivior and Braeburn's injectable buprenorphine products simultaneously; here's a side-by-side look at the advantages and disadvantages of each.

As US FDA Commissioner Scott Gottlieb has touted the agency’s commitment to promoting the development of new opioid use disorder medications, the agency is likely to approve two new subcutaneous, long-acting buprenorphine treatments that have been billed as formulations designed to improve adherence and reduce abuse.

The Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee recently convened in back-to-back joint sessions on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers